An experimental obesity drug helped patients lose up to 25% of their body weight in a mid-stage clinical trial, the strongest result reported for any weight-loss medication to date.
The drug, retatrutide, is made by Eli Lilly. It works by targeting three hormones at once: GLP-1, GIP, and glucagon. That triple approach sets it apart from existing drugs like Wegovy and Zepbound, which target one or two of those pathways.
Trial results showed patients on the highest dose lost roughly a quarter of their starting weight over the study period. That figure exceeds the roughly 15% to 22% weight loss seen with current market leaders.
Researchers reported the findings from a Phase 2 trial, which typically enrolls a few hundred patients and tests whether a drug works well enough to justify larger studies. The results were strong enough to push retatrutide into late-stage testing.
The stakes are high. More than 40% of American adults are obese, according to the Centers for Disease Control and Prevention. Obesity raises the risk of heart disease, type 2 diabetes, and certain cancers.
Existing drugs in this class have already changed the market. Novo Nordisk's Wegovy and Eli Lilly's Zepbound have seen explosive demand, and both companies have struggled to keep up with supply.
Retatrutide could intensify that competition. Larger trials will determine whether the weight loss holds up and whether the drug is safe enough for widespread use. Side effects in the class, including nausea and vomiting, have led some patients to stop treatment.
Doctors caution that no drug replaces diet and exercise, and the long-term effects of rapid weight loss remain under study. Questions also remain about whether patients must stay on the drug indefinitely to keep the weight off.
The trial data was published in a peer-reviewed journal and presented at a medical conference. Lilly has not said when it plans to seek regulatory approval.
If approved, retatrutide would become the third major obesity drug from the GLP-1 family to reach the U.S. market, giving patients another option in a field that barely existed five years ago.
